Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...
Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
More than 1,400 participants across 65+ countries underscores accelerating adoption of model-informed workflows and growing demand for applied modeling expertise Simulations Plus, Inc. (Nasdaq: SLP) ( ...
The International Council for Harmonisation (ICH) released a widely anticipated timetable detailing its plans to issue general guidance on model-informed drug development (MIDD) approaches in drug ...
Details on the US Food and Drug Administration’s (FDA) plans for launching a pilot project on model-informed drug development (MIDD) began trickling out on Monday with a Federal Register notice.
RADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results